GSK 的 Shingrix 疫苗有效率为 79.7-82%。 GSK's Shingrix vaccine maintains 79.7-82% efficacy.

葛兰素史克公司宣布，其重磅带状疱疹疫苗 Shingrix 的长期数据显示，对于 50 岁及以上的参与者，接种疫苗后 6 至 11 年的有效率为 79.7%，接种后 11 年的有效率仍高达 82%。 GSK announced that long-term data from its blockbuster shingles vaccine, Shingrix, showed 79.7% efficacy in participants aged 50 and above, six to 11 years after vaccination, with efficacy remaining high at 82% at year 11 post-vaccination. 该数据来自一项长期跟踪后期试验，该试验对参与者在初次接种疫苗后长达 11 年的跟踪。 The data comes from a long-term follow-up, late-stage trial that tracked participants for up to 11 years after initial vaccination.